Kineta Shares Are Trading Higher After the Company Announced That It Entered Into an Exclusivity and Right of First Offer Agreement With TuHURA Biosciences to Grant the Immune-oncology Company Exclusive Rights to Acquire Its Anti-VISTA Antibody.
Kineta Shares Are Trading Higher After the Company Announced That It Entered Into an Exclusivity and Right of First Offer Agreement With TuHURA Biosciences to Grant the Immune-oncology Company Exclusive Rights to Acquire Its Anti-VISTA Antibody.
Kineta的股票價格上漲，因爲公司宣佈與TuHURA生物科技簽署排他性和先購權協議，授予免疫腫瘤公司其抗VISTA抗體的獨家收購權。
Kineta Shares Are Trading Higher After the Company Announced That It Entered Into an Exclusivity and Right of First Offer Agreement With TuHURA Biosciences to Grant the Immune-oncology Company Exclusive Rights to Acquire Its Anti-VISTA Antibody.
Kineta的股票價格上漲，因爲公司宣佈與TuHURA生物科技簽署排他性和先購權協議，授予免疫腫瘤公司其抗VISTA抗體的獨家收購權。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間